MUSC Health has expanded use of SoundHound AI’s Emily voice agent across retail and specialty pharmacy phone lines, putting the company back in focus after a rough stretch for its shares. The move is one of the first agentic voice deployments for an Epic system, and it gives SoundHound AI a fresh real-world reference point at a moment when investors have been looking for proof that the business can turn interest into revenue.
The market has noticed. SoundHound AI shares rose 6.89% in the latest day and 4.49% over the past seven days, even though they remain down 30.42% over 90 days and 41.63% over the past year. Over three years, the stock is still up more than 3x, a reminder of how quickly sentiment has swung around the name.
That swing is why Soun stock is being searched now. The latest close was $6.52, while analysts following the company see fair value at about $13.14, roughly double the recent price. The gap is large enough to keep the valuation debate alive, especially with the shares carrying a price-to-sales ratio of 15.3x versus a peer average of about 4.4x and a fair ratio benchmark of 3.1x.
The problem is that the deployment headline does not erase the financial picture underneath it. SoundHound AI still runs sizeable losses and depends on large, sometimes uneven enterprise deals, which means a single hospital system expansion can matter for visibility without yet proving a durable step-up in the business. Investors are being asked to decide whether Emily’s wider use at MUSC Health is the start of a larger operating shift or just another reminder of how far the stock has to run before fundamentals catch up.
For now, the expansion is the clearest new development, and it is the one that can move the story today. What comes next is whether SoundHound AI can turn these deployments into repeatable revenue at a pace that makes the valuation argument easier to defend.
